Naxitamab-gqgk
What Is naxitamab-gqgk?[edit | edit source]
- Naxitamab-gqgk (Danyelza) is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF).
What are the uses of this medicine?[edit | edit source]
Danyelza is a prescription medicine used in combination with a medicine called granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat children 1 year of age and older and adults with high-risk neuroblastoma in the bone or bone marrow that:
- has come back (relapsed) or that did not respond to previous treatment (refractory), and
- has shown a partial response, minor response, or stable disease to prior therapy.
How does this medicine work?[edit | edit source]
Naxitamab-gqgk binds to the glycolipid GD2. GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves. In vitro, naxitamab-gqgk was able to bind to cell surface GD2 and induce complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC).
Who Should Not Use this medicine ?[edit | edit source]
- Danyelza cannot be used in patients with a history of severe hypersensitivity reaction to naxitamab-gqgk.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2020.
How should this medicine be used?[edit | edit source]
- The recommended dosage of Danyelza is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on Days 1, 3, and 5 of each treatment cycle.
- Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks.
- Subsequent cycles may be repeated every 8 weeks.
- Administer GM-CSF subcutaneously prior to and during each treatment cycle as recommended.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- This medicine is avaialable as Injection: 40 mg/10 mL (4 mg/mL) clear to slightly opalescent and colorless to slightly yellow solution in a single-dose vial.
This medicine is available in fallowing brand namesː
- Danyelza
What side effects can this medication cause?[edit | edit source]
Common possible side effects and laboratory abnormalities of this medicine include:
- pain, tachycardia, vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability
- decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased platelet count, decreased potassium, increased alanine aminotransferase, decreased glucose, decreased calcium, decreased albumin, decreased sodium, and decreased phosphate
What special precautions should I follow?[edit | edit source]
- Permanently discontinue this medication if Peripheral neuropathy, neurological disorders of the eye, and prolonged urinary retention have also occurred.
- Advise females of reproductive potential of potential risk to a fetus and to use effective contraception.
- Monitor blood pressure during and after infusion as recommended.
- Withhold, reduce infusion rate, or discontinue based on severity.
- Danyelza can cause serious infusion reactions requiring urgent intervention including fluid resuscitation, administration of bronchodilators and corticosteroids, intensive care unit admission, infusion rate reduction or interruption of Danyelza infusion.
- Permanently discontinue Danyelza in patients who develop transverse myelitis.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- Based on its mechanism of action, Danyelza may cause fetal harm when administered to pregnant women.
- There are no available data on the use of Danyelza in pregnant women.
Can this medicine be used in children?[edit | edit source]
- The safety and effectiveness of Danyelza, in combination with GM-CSF have been established in pediatric patients 1 year of age and older.
- Safety and effectiveness have not been established in pediatric patients younger than 1 year of age.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store Danyelza vial refrigerated at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light until time of use.
Naxitamab-gqgk Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Naxitamab-gqgk Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju